Updated trends in incidence and mortality of pancreatic cancer. an analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

786 Background: Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. The prognosis for pancreatic cancer remains poor despite advances in cancer therapy. In this study, we provide updated trends in pancreatic cancer incidence and mortality using the SEER database, with a subset analysis of age and gender. Methods: Using the SEER Stat software, we gathered data from the Surveillance, Epidemiology, and End Results (SEER) database (2000–2021). We employed Jointpoint regression to analyze the secular trend of incidence and incidence-based mortality (IBM), which we classified and arranged according to age and sex. Results: 235,116 cases met the inclusion criteria for our study. These included diagnosed cases of pancreatic cancer from 2000 to 2001. The total age-adjusted incidence rate was 12.5 per 100,000. 118,791 (50.5%) were males and 116,325 (49.5%) were female. While the annual percentage change (APC) from 2000-2019 was 0.92 (p < 0.05), signifying an annual cumulative increase, APC from 2019-2021 was -0.085, signifying an annual cumulative decrease. For males, the APC was 0.94 (p < 0.05) from 2000 to 2018 and -0.55 from 2018-2021, and for females, the APC was -0.89 (p < 0.05) from 2019-2021. The pancreatic cancer IBM APC from 2000-2022 was 22.60 (p < 0.05) and 0.54 (p < 0.05) from 2002-2021. For males, IBM APC was 21.10 (p < 0.05) from 2000-2002 and 0.58 from 2002-2021. For females, IBM APC was 25.15 from 2000-2002 and 0.42 from 2002-2021. We also studied pancreatic cancer IBM based on age. For 30-49 years, APC from 2000-2002 was 34.65 (p < 0.05), and -0.64 (p < 0.05) from 2002-2021. For 50-69 years, APC from 2000-2002 was 28.05 (p < 0.05) and 0.3 from 2002-2021. For 70+ years, APC from 2000-2002 was 21.28 (p < 0.05) and 0.73 from 2002-2021. Conclusions: There was a statistically significant rise in incidence and incidence-based mortality across the board, underscoring the need for improved diagnostic and therapeutic modalities of management of pancreatic cancer.